

Intercept Pharmaceuticals, Inc. Investor Relations Department 450 West 15th Street, Suite 505 New York, NY 10011 United States

Visit IR website ☐ Sign-up for email alerts ☐

122.01
4:00 PM ET Jun 27, 2017
0.00 (0.000%)
N/A - N/A
96.63 - 177.93
100

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Stock Performance**



## Press Releases [View all]

Jun 22, 2017

Intercept's Ocaliva® (obeticholic acid) Receives 2017 Galien Chemical Synthesis Drug Award in Italy

Jun 12, 2017

Intercept Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes

May 25, 2017

Health Canada Grants Approval for Ocaliva<sup>™</sup> (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis (PBC)

May 19, 2017

Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid)

May 17, 2017

Intercept to Present at Upcoming Conferences

## Financials [View all]

First Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

May 1, 2017

Proxy Statement (DEF 14A)

May 10, 2017

Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)

Aug 9, 2016

Quarterly Report (10-Q)